Your browser doesn't support javascript.
loading
CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma.
Godet, Cendrine; Brun, Anne-Laure; Couturaud, Francis; Laurent, François; Frat, Jean-Pierre; Marchand-Adam, Sylvain; Gagnadoux, Frédéric; Blanchard, Elodie; Taillé, Camille; Philippe, Bruno; Hirschi, Sandrine; Andréjak, Claire; Bourdin, Arnaud; Chenivesse, Cécile; Dominique, Stéphane; Mangiapan, Gilles; Murris-Espin, Marlène; Rivière, Frédéric; Garcia, Gilles; Blanc, François-Xavier; Goupil, François; Bergeron, Anne; Flament, Thomas; Priou, Pascaline; Mal, Hervé; de Keizer, Joe; Ragot, Stéphanie; Cadranel, Jacques.
Afiliación
  • Godet C; Service de Pneumologie B et Transplantation pulmonaire, Université Paris Cité, Assistance Publique - Hôpitaux de Paris, Hôpital Bichat, Paris, France. Electronic address: cendrine.godet@aphp.fr.
  • Brun AL; Service de Radiologie, Hôpital Foch, Suresnes, France.
  • Couturaud F; Université Brest, INSERM U1304-GETBO, CHU Brest, Département de Médecine Interne et Pneumologie, CIC INSERM 1412, CHU Brest, FCRIN INNOVTE, France; Département de Médecine Interne et Pneumologie, CHU Brest, France.
  • Laurent F; Université Bordeaux, INSERM, CRCTB, U 1045, F-33000 Bordeaux, France.
  • Frat JP; Médecine Intensive Réanimation, CHU Poitiers, Poitiers, France; Université Poitiers, INSERM, CIC 1402, IS-ALIVE, CHU Poitiers, Poitiers, France.
  • Marchand-Adam S; Université François Rabelais, Tours, INSERM 1100, Tours, France; Service de pneumologie et explorations fonctionnelles respiratoires, CHRU de Tours, Tours, France.
  • Gagnadoux F; Service de Pneumologie et Allergologie, Centre Hospitalier Universitaire d'Angers, Angers, France.
  • Blanchard E; Service de Pneumologie, CHU Bordeaux site Haut Lévêque Pessac, France.
  • Taillé C; Service de Pneumologie et Centre de Référence constitutif des Maladies Pulmonaires Rares, AP-HP Nord-Université Paris Cité, Hôpital Bichat, INSERM, UMR 1152, Paris, France.
  • Philippe B; Service de Pneumologie, Hôpital NOVO, Pontoise, France.
  • Hirschi S; Service de Pneumologie, Centre de Compétence des Maladies Pulmonaires Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Andréjak C; Service de Pneumologie, CHU Amiens Picardie, Amiens, France; Université Picardie Jules Verne, UR 4294, CHU Amiens Picardie, Amiens, France.
  • Bourdin A; Université Montpellier, INSERM, CNRS, CHU Montpellier, PhyMed Exp, Montpellier, France.
  • Chenivesse C; Université Lille, CNRS, INSERM, CHU Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-5900 Lille, France; CRISALIS, F-CRIN Network, INSERM US015, Toulouse, France.
  • Dominique S; Département de Pneumologie, Université Rouen Hospital, Rouen, France.
  • Mangiapan G; Service de pneumologie CHI de Créteil, Créteil, France.
  • Murris-Espin M; Service de Pneumologie, CRCM adulte et Transplantation pulmonaire, Clinique des Voies Respiratoires, CHU de Toulouse, Hôpital Larrey, Toulouse, France.
  • Rivière F; Service de Pneumologie, Centre Hospitalier Universitaire Côte de Nacre, Caen, France.
  • Garcia G; School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France; INSERM UMR-S 999 «Pulmonary Hypertension: Pathophysiology and Novel Therapies¼, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Department of Respiratory and Intensive Care Medicine, Assistance Publique - Hôpitaux de Pa
  • Blanc FX; Nantes Université, CHU Nantes, INSERM, Service de Pneumologie, CIC 1413, l'institut du thorax, Nantes, France.
  • Goupil F; Service de pneumologie, CH Le Mans, Le Mans, France.
  • Bergeron A; Division of Pulmonology, Geneva University Hospitals, Geneva, Switzerland.
  • Flament T; Service de pneumologie et explorations fonctionnelles respiratoires, CHRU de Tours, Tours, France.
  • Priou P; Service de Pneumologie et Allergologie, Centre Hospitalier Universitaire d'Angers, Angers, France.
  • Mal H; Service de Pneumologie B et Transplantation pulmonaire, Université Paris Cité, Assistance Publique - Hôpitaux de Paris, Hôpital Bichat, Paris, France.
  • de Keizer J; Université Poitiers, INSERM, CIC-1402, Biostatistics, Poitiers, France, Faculté de Médecine et de Pharmacie de Poitiers, Poitiers, France.
  • Ragot S; Université Poitiers, INSERM, CIC-1402, Biostatistics, Poitiers, France, Faculté de Médecine et de Pharmacie de Poitiers, Poitiers, France.
  • Cadranel J; Service de Pneumologie et Oncologie Thoracique, Centre constitutif Maladies pulmonaires rares, Université Paris Sorbonne, Assistance Publique - Hôpitaux de Paris, Hôpital Tenon, Paris, France.
Chest ; 165(6): 1307-1318, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38387646
ABSTRACT

BACKGROUND:

One of the major challenges in managing allergic bronchopulmonary aspergillosis remains consistent and reproducible assessment of response to treatment. RESEARCH QUESTION What are the most relevant changes in CT scan parameters over time for assessing response to treatment? STUDY DESIGN AND

METHODS:

In this ancillary study of a randomized clinical trial (NebuLamB), patients with asthma with available CT scan and without exacerbation during a 4-month allergic bronchopulmonary aspergillosis exacerbation treatment period (corticosteroids and itraconazole) were included. Changed CT scan parameters were assessed by systematic analyses of CT scan findings at initiation and end of treatment. CT scans were assessed by two radiologists anonymized to the clinical data. Radiologic parameters were determined by selecting those showing significant changes over time. Improvement of at least one, without worsening of the others, defined the radiologic response. Agreement between radiologic changes and clinical and immunologic responses was likewise investigated.

RESULTS:

Among the 139 originally randomized patients, 132 were included. We identified five CT scan parameters showing significant changes at end of treatment mucoid impaction extent, mucoid impaction density, centrilobular micronodules, consolidation/ground-glass opacities, and bronchial wall thickening (P < .05). These changes were only weakly associated with one another, except for mucoid impaction extent and density. No agreement was observed between clinical, immunologic, and radiologic responses, assessed as an overall response, or considering each of the parameters (Cohen κ, -0.01 to 0.24).

INTERPRETATION:

Changes in extent and density of mucoid impaction, centrilobular micronodules, consolidation/ground-glass opacities, and thickening of the bronchial walls were found to be the most relevant CT scan parameters to assess radiologic response to treatment. A clinical, immunologic, and radiologic multidimensional approach should be adopted to assess outcomes, probably with a composite definition of response to treatment. TRIAL REGISTRATION ClinicalTrials.gov; No. NCT02273661; URL www. CLINICALTRIALS gov).
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Aspergilosis Broncopulmonar Alérgica / Asma / Tomografía Computarizada por Rayos X / Itraconazol / Antifúngicos Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Chest Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Aspergilosis Broncopulmonar Alérgica / Asma / Tomografía Computarizada por Rayos X / Itraconazol / Antifúngicos Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Chest Año: 2024 Tipo del documento: Article